

World Companion Diagnostics and Liquid Biopsy Summit APAC to Unite 100+ Precision Medicine Experts

10 October 2024 | News

Bringing biomarkers, companion diagnostics, and liquid biopsy experts from across the Asia-Pacific region together for the very first time, the World Companion Diagnostics & Liquid Biopsy Summit APAC will take place at the Conrad Centennial, Singapore this November 13-14, 2024.



**A Comprehensive Framework for
Successful Drug-Companion Diagnostic
Co-Development & Robust Biomarker
Strategies Towards Accessible &
Affordable Precision Therapies in the APAC
Market for Improved Patient Outcomes**

 **NOVEMBER 13-14, 2024**  **SINGAPORE**  **CDX-LBX-SUMMIT-APAC.COM**

This exciting forum will gather the field to discuss the latest advancements in NGS, biomarker development, clinical trial assay development and more to expedite precision therapies to patients in need.

Across two days of industry-led content, this conference offers unique opportunities to network with thought leaders, gain insights into the latest research and emerging trends, engage in discussions with 100 fellow industry leaders, and exchange ideas with your peers to foster collaborations and drive innovation in healthcare.

19+ expert speakers from biopharma and service and solution providers will provide data-driven insights into the region's most pressing challenges of regulation, reimbursement, market access and more.

Here's just a few reasons you should attend:

- Navigate rapidly evolving regulatory guidelines across the region to streamline approvals and enable greater patient access to precision therapeutics with **Bristol Myers Squibb, Kyowa Kirin, and Johnson & Johnson**
- Overcome barriers to market access with robust precision medicine strategies from clinical trials to companion diagnostic launch and partnership selection with **Bristol Myers Squibb, Daiichi Sankyo, and Omico**
- Gain insights into how more sensitive and specific liquid biopsies are enabling earlier disease diagnosis and more effective response monitoring with **Johnson & Johnson, Fudan University, and Takeda**
- Learn how novel technologies including digital pathology and machine learning can optimize patient selection with enhancing pre-screening for clinical trials with **Sanofi**
- Discover how to more accurately stratify patients with robust clinical biomarker development with **Harbour Biomed and OBI Pharma**

Access the full program to learn more: <https://ter.li/ry9lse>

This meeting is free to attend for drug developers and researchers (subject to terms and conditions), visit the website to learn more and register your place: <https://ter.li/qiity0>